Compare Adaptive Biotechnologies Corp (ADPT) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Grab Holdings Ltd. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Grab Holdings Ltd. trades at $3.81 (market cap $16.07B). The key difference: Grab Holdings Ltd. is far larger — about 4.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| ADPT | GRAB | |
|---|---|---|
Market Cap | $3.33B | $16.07B |
Sector | Health | Technology |
52-Week High | $22.37 | $6.45 |
52-Week Low | $10.24 | $3.27 |
Enterprise Value | $3.19B | $11.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GRAB trades at $3.93, up 0.77% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with net income of $268 million and revenue growth to $3.37 billion. Recent news highlights the departure of Uber's CEO from GRAB's board, causing a brief stock dip. Analyst consensus is strongly bullish with a $5.60 price target, representing significant upside potential from current levels.
GRAB's outlook is positive due to sustained revenue growth and recent profitability, though high P/E of 96.25 suggests elevated expectations. Key risks include competitive pressures in Southeast Asia and reliance on continued user growth. The stock offers growth exposure to the region's digital economy, supported by strong analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
